Treatment of Hodgkin lymphoma: a 50-year perspective.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
George P
GP
Canellos
Saul A
SA
Rosenberg
Jonathan W
JW
Friedberg
T Andrew
TA
Lister
Vincent T
VT
Devita
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000266:history / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001761:Bleomycin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005060:Europe / Q000453:epidemiology; D049673:History, 20th Century; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000266:history / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone